Immune dynamics during blinatumomab therapy in B-cell acute lymphoblastic leukemia
Blinatumomab, a CD19×CD3 bispecific T-cell engager, has become an important component of therapy for B-cell acute lymphoblastic leukemia (B-ALL) across relapsed/refractory, measurable residual disease, consolidation, and selected frontline settings. Its activity depends on functional endogenous T cells and therefore provides a clinically relevant model for studying treatment-associated immune dynamics. Following treatment initiation, circulating T cells undergo rapid redistribution and activation, followed by recovery and expansion of effector and memory populations. In parallel, profound CD19-positive B-cell depletion produces a slower and heterogeneous disturbance of humoral immunity, while transient cytokine release is concentrated predominantly in the early phase of the first treatment cycle. Sustained immune engagement may also be accompanied by inhibitory checkpoint signaling and exhaustion-associated T-cell dysfunction in a subset of patients. Beyond peripheral blood, the bone marrow niche and anatomical compartmentalization may modify the interaction between effector T cells and leukemic targets, although direct evidence linking specific microenvironmental components to clinical blinatumomab resistance remains limited. Resistance and relapse are multifactorial and include reduced or lost CD19 expression, lineage plasticity, inadequate T-cell fitness, treatment-associated T-cell dysfunction, and extramedullary escape. This review synthesizes current evidence on the temporal and compartment-specific immune changes associated with blinatumomab therapy and discusses their implications for response, toxicity, resistance, immune recovery, and future biomarker-guided treatment strategies.
Authors
- 胡群
- A G Liu (ORCID: https://orcid.org/0009-0001-1190-385X)
- Jiale Liu
- Yijie Cai
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Clinical and Experimental Medicine
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1007/s10238-026-02377-z
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00